title: Aldehyded Dextran and ε -Poly(L-lysine) Hydrogel as Nonviral Gene Carrier.
abstract: Background. The expression term of the gene transfected in cells needs to belong enough inorder to make a gene therapy clinically effective. The controlled release of the transfected gene can be utilized. The new biodegradable hydrogel material created by 20 w/w% aldehyded dextran and 10 w/w% ε -poly(L-lysine) (ald-dex/PLL) was developed. We examined whether it could be as a nonviral carrier of the gene transfer. Methods. A plasmid (Lac-Z) was mixed with ald-dex/PLL. An in vitro study was performed to assess the expression of Lac-Z with X-gal stain after gene transfer into the cultured 293 cells and bone marrow cells. As a control group, PLL was used as a cationic polymer. Results. We confirmed that the transfection efficiency of the ald-dex/PLL had a higher transfection efficiency than PLL in 293 cells (plasmid of 2  μ g: ald-dex/PLL 1.1%, PLL 0.23%, plasmid of 16  μ g: ald-dex/PLL 1.23%, PLL 0.48%). In bone marrow cells, we confirmed the expression of Lac-Z by changing the quantity of aldehyded dextran. In the groups using ald-dextran of the quantity of 1/4 and 1/12 of PLL, their transfection efficiency was 0.43% and 0.41%, respectively. Conclusions. This study suggested a potential of using ald-dex/PLL as a non-carrier for gene transfer.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Togo
authors.forename: Katsu
authors.initials: K
authors.lastname: Takahashi
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Saito
authors.forename: Honoka
authors.initials: H
authors.lastname: Kiso
authors.forename: Boyen
authors.initials: B
authors.lastname: Huang
authors.forename: Hiroko
authors.initials: H
authors.lastname: Tsukamoto
authors.forename: Suong-Hyu
authors.initials: SH
authors.lastname: Hyon
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Bessho
references.citation: J Drug Target. 2003 Aug;11(7):407-14
references.pmid: 15203929
references.citation: Am J Respir Cell Mol Biol. 1999 May;20(5):1081-6
references.pmid: 10226080
references.citation: J Control Release. 2002 Apr 23;80(1-3):333-43
references.pmid: 11943409
references.citation: J Thorac Cardiovasc Surg. 2007 Nov;134(5):1241-8
references.pmid: 17976456
references.citation: Curr Pharm Des. 2002;8(21):1917-28
references.pmid: 12171527
references.citation: J Biosci Bioeng. 2007 Jun;103(6):547-56
references.pmid: 17630127
references.citation: Gene Ther. 2000 Jan;7(1):31-4
references.pmid: 10680013
references.citation: Hum Gene Ther. 1995 Sep;6(9):1129-44
references.pmid: 8527471
references.citation: Biol Pharm Bull. 1994 Feb;17(2):275-82
references.pmid: 8205127
references.citation: Mol Ther. 2000 Oct;2(4):302-17
references.pmid: 11020345
references.citation: Drug Discov Today. 2005 Dec;10(23-24):1639-46
references.pmid: 16376824
references.citation: Bioconjug Chem. 1998 Jul-Aug;9(4):476-81
references.pmid: 9667949
references.citation: J Control Release. 2003 Jun 24;90(2):207-16
references.pmid: 12810303
references.citation: Pharm Res. 2000 Feb;17(2):113-26
references.pmid: 10751024
references.citation: Gene Ther. 2002 Dec;9(24):1647-52
references.pmid: 12457277
references.citation: Nat Med. 1999 Jun;5(6):707-10
references.pmid: 10371512
references.citation: J Med Chem. 2002 Apr 25;45(9):1817-24
references.pmid: 11960493
references.citation: Bioconjug Chem. 1998 Mar-Apr;9(2):292-9
references.pmid: 9548547
references.citation: Gene Ther. 2003 Aug;10(17):1420-8
references.pmid: 12900756